BDX Quantitative Stock Analysis

Validea's guru fundamental report indicates that Becton Dickinson (BDX) receives a 91% rating based on their P/E/Growth Investor model, which is based on Peter Lynch's investment strategy; a score above 90% typically indicates strong interest. The rating reflects BDX's strong balance sheet and reasonable price relative to earnings growth, with the firm passing key criteria such as P/E/growth ratio, sales and P/E ratio, inventory to sales, EPS growth rate, and total debt/equity ratio.

Analysis

Becton Dickinson and Co. (BDX) has garnered a significant 91% rating from Validea's P/E/Growth Investor model, which is predicated on the investment principles of Peter Lynch, indicating strong interest from this strategic perspective. This model emphasizes companies with reasonable valuations relative to their earnings growth and robust balance sheets. As a large-cap growth stock in the Medical Equipment & Supplies industry, BDX successfully passed several critical tests within this framework, including the P/E/Growth ratio, Sales and P/E ratio, Inventory to Sales ratio, EPS growth rate, and Total Debt/Equity ratio. These passes underscore the company's favorable positioning according to Lynch's criteria. However, the model assigned a 'Neutral' rating to BDX's Free Cash Flow and Net Cash Position, suggesting these specific financial aspects may warrant closer scrutiny despite the overall positive assessment. The sentiment surrounding this report for BDX is strongly positive, reflecting the high model score and the passing of multiple fundamental checks.

Key Decisions for Investors

• Investors employing a growth-at-a-reasonable-price (GARP) strategy, particularly those who favor Peter Lynch's investment criteria, should consider BDX a potentially attractive opportunity given its high model score and positive assessment on key growth and balance sheet metrics.
• While BDX demonstrates strength in areas like EPS growth and debt management according to the Lynch model, the 'Neutral' ratings for Free Cash Flow and Net Cash Position suggest these are areas for investors to monitor or investigate further before making investment decisions.
• Considering the strong alignment with a renowned growth-focused investment strategy, BDX may warrant a bullish outlook for investors seeking large-cap exposure in the Medical Equipment & Supplies sector, provided the neutral cash flow metrics are acceptable within their risk tolerance.